Free Trial

Nuveen LLC Purchases Shares of 3,206,466 Sanofi (NASDAQ:SNY)

Sanofi logo with Medical background

Key Points

  • Nuveen LLC acquired a new stake in Sanofi by purchasing 3,206,466 shares, valued at approximately $177.8 million, during the first quarter of the year.
  • Several institutional investors, including Cardinal Capital Management and AdvisorNet Financial Inc, increased their stakes in Sanofi, demonstrating growing confidence in the company.
  • Sanofi's latest earnings report showed $0.90 earnings per share, missing expectations, while revenue decreased by 7% year-over-year, totaling $11.34 billion.
  • Looking to export and analyze Sanofi data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Nuveen LLC purchased a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 3,206,466 shares of the company's stock, valued at approximately $177,831,000. Nuveen LLC owned 0.13% of Sanofi as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Cardinal Capital Management lifted its position in shares of Sanofi by 0.3% in the 1st quarter. Cardinal Capital Management now owns 69,004 shares of the company's stock worth $3,827,000 after purchasing an additional 199 shares during the period. Gradient Investments LLC lifted its position in shares of Sanofi by 2.1% in the 1st quarter. Gradient Investments LLC now owns 9,764 shares of the company's stock worth $542,000 after purchasing an additional 200 shares during the period. Perigon Wealth Management LLC lifted its position in shares of Sanofi by 3.1% in the 1st quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company's stock worth $367,000 after purchasing an additional 201 shares during the period. Beacon Financial Group lifted its position in shares of Sanofi by 1.6% in the 1st quarter. Beacon Financial Group now owns 14,398 shares of the company's stock worth $799,000 after purchasing an additional 222 shares during the period. Finally, AdvisorNet Financial Inc lifted its position in shares of Sanofi by 16.4% in the 1st quarter. AdvisorNet Financial Inc now owns 1,613 shares of the company's stock worth $89,000 after purchasing an additional 227 shares during the period. Hedge funds and other institutional investors own 14.04% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday. Morgan Stanley set a $56.00 target price on shares of Sanofi in a research report on Monday, June 2nd. Guggenheim reissued a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Finally, BNP Paribas initiated coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target for the company. Two analysts have rated the stock with a hold rating, five have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $62.00.

Get Our Latest Analysis on Sanofi

Sanofi Trading Up 0.2%

Shares of NASDAQ SNY opened at $47.21 on Tuesday. Sanofi has a 1 year low of $44.73 and a 1 year high of $60.12. The stock has a market cap of $115.92 billion, a P/E ratio of 11.35, a price-to-earnings-growth ratio of 1.13 and a beta of 0.48. The firm has a 50-day moving average of $48.63 and a 200 day moving average of $51.93. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The firm had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm's revenue for the quarter was down 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.73 earnings per share. As a group, sell-side analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

See Also

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Sanofi Right Now?

Before you consider Sanofi, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.

While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Overlooked Stocks Riding the AI Data Center Boom
3 Growth Stock Winners to Watch And 3 to Avoid
3 Growth Stocks That Could Pop Before Summer Ends

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines